Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 199 av 199 resultater
Tid
Selskap
Tittel
Sektor
Kategori
04 Jul 2022
18:45 CEST
INVENTIVA
Point sur la situation de trésorerie d'Inventiva et sur le crédit conclu avec la Banque Européenne d'Investissement
20103010 Biotechnology
Other subject
16 Jun 2022
22:00 CEST
INVENTIVA
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
20103010 Biotechnology
Other subject
16 Jun 2022
22:00 CEST
INVENTIVA
Inventiva organise un webcast avec des leaders d’opinion à l’occasion de l’EASL International Liver Congress™ 2022
20103010 Biotechnology
Other subject
09 Jun 2022
22:00 CEST
INVENTIVA
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
20103010 Biotechnology
Other subject
09 Jun 2022
22:00 CEST
INVENTIVA
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
20103010 Biotechnology
Other subject
07 Jun 2022
22:00 CEST
INVENTIVA
Inventiva joins the Euronext Tech Leaders segment
20103010 Biotechnology
Other subject
07 Jun 2022
22:00 CEST
INVENTIVA
Inventiva intègre le segment Tech Leaders d’Euronext
20103010 Biotechnology
Other subject
03 Jun 2022
22:00 CEST
INVENTIVA
Inventiva annonce la présentation d’un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association
20103010 Biotechnology
Other subject
03 Jun 2022
22:00 CEST
INVENTIVA
Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association
20103010 Biotechnology
Other subject
23 May 2022
22:00 CEST
INVENTIVA
Inventiva annonce sa participation à plusieurs conférences investisseurs en mai et juin 2022
20103010 Biotechnology
Other subject
23 May 2022
22:00 CEST
INVENTIVA
Inventiva announces participation at several investors conferences in May and June 2022
20103010 Biotechnology
Other subject
20 May 2022
22:00 CEST
INVENTIVA
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunie le 19 mai 2022
20103010 Biotechnology
General meeting / Board Meeting
20 May 2022
22:00 CEST
INVENTIVA
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022
20103010 Biotechnology
General meeting / Board Meeting
19 May 2022
22:00 CEST
INVENTIVA
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022
20103010 Biotechnology
Other subject
19 May 2022
22:00 CEST
INVENTIVA
DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISÉ PAR L'ASSEMBLÉE GÉNÉRALE ORDINAIRE DU 19 MAI 2022
20103010 Biotechnology
Other subject
16 May 2022
22:00 CEST
INVENTIVA
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
20103010 Biotechnology
Other subject
16 May 2022
22:00 CEST
INVENTIVA
Inventiva publie ses informations financières du 1er trimestre 2022 et fait un point sur ses développements cliniques
20103010 Biotechnology
Other subject
16 May 2022
08:00 CEST
INVENTIVA
Inventiva secures a €50 million credit facility from the European Investment Bank
20103010 Biotechnology
Other subject
16 May 2022
08:00 CEST
INVENTIVA
Inventiva obtient un crédit d’un montant de 50 millions d’euros de la part de la Banque Européenne d’Investissement
20103010 Biotechnology
Other subject
28 Apr 2022
16:35 CEST
INVENTIVA
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022
20103010 Biotechnology
General meeting / Board Meeting
28 Apr 2022
16:35 CEST
INVENTIVA
Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2022
20103010 Biotechnology
General meeting / Board Meeting
28 Apr 2022
16:30 CEST
INVENTIVA
Combined General Meeting of May 19, 2022 - Availability of the preparatory documents
20103010 Biotechnology
General meeting / Board Meeting
28 Apr 2022
16:30 CEST
INVENTIVA
Assemblée Générale Mixte du 19 mai 2022 - Modalités de mise à disposition des documents préparatoires
20103010 Biotechnology
General meeting / Board Meeting
07 Apr 2022
22:00 CEST
INVENTIVA
Inventiva annonce la présentation d’un abstract scientifique lors de la prochaine International Conference on Fatty Liver
20103010 Biotechnology
Other subject
07 Apr 2022
22:00 CEST
INVENTIVA
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
20103010 Biotechnology
Other subject
11 Mar 2022
22:44 CET
INVENTIVA
Inventiva annonce le dépôt de son Document d'Enregistrement Universel 2021 et de son Rapport Annuel 2021 (« Form 20-F »)
20103010 Biotechnology
Other subject
11 Mar 2022
22:44 CET
INVENTIVA
Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
20103010 Biotechnology
Other subject
08 Mar 2022
08:00 CET
INVENTIVA
Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
20103010 Biotechnology
Other subject
08 Mar 2022
08:00 CET
INVENTIVA
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
20103010 Biotechnology
Other subject
07 Mar 2022
22:26 CET
INVENTIVA
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
20103010 Biotechnology
Income
07 Mar 2022
22:26 CET
INVENTIVA
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis
20103010 Biotechnology
Income
07 Mar 2022
22:00 CET
INVENTIVA
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis
20103010 Biotechnology
Income
07 Mar 2022
22:00 CET
INVENTIVA
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis
20103010 Biotechnology
Income
01 Mar 2022
22:00 CET
INVENTIVA
Inventiva announces participation at several conferences in March 2022
20103010 Biotechnology
Other subject
01 Mar 2022
22:00 CET
INVENTIVA
Inventiva annonce sa participation à plusieurs conférences investisseurs en mars 2022
20103010 Biotechnology
Other subject
28 Feb 2022
22:00 CET
INVENTIVA
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
20103010 Biotechnology
Other subject
28 Feb 2022
22:00 CET
INVENTIVA
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2021
20103010 Biotechnology
Other subject
14 Feb 2022
22:00 CET
INVENTIVA
Inventiva reports cash position and revenues for Full-Year 2021
20103010 Biotechnology
Sales
14 Feb 2022
22:00 CET
INVENTIVA
Inventiva publie sa position de trésorerie et son chiffre d’affaires pour l’exercice 2021
20103010 Biotechnology
Sales
31 Jan 2022
22:00 CET
INVENTIVA
Inventiva reçoit un paiement d'étape de 4 M€ de la part d’AbbVie suite au lancement de l’étude de Phase IIb avec cedirogant
20103010 Biotechnology
Other subject
31 Jan 2022
22:00 CET
INVENTIVA
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
20103010 Biotechnology
Other subject
20 Jan 2022
22:00 CET
INVENTIVA
Inventiva annonce sa participation à plusieurs conférences investisseurs en janvier et février 2022
20103010 Biotechnology
Other subject
20 Jan 2022
22:00 CET
INVENTIVA
Inventiva announces participation at several conferences in January and February 2022
20103010 Biotechnology
Other subject
14 Jan 2022
08:00 CET
INVENTIVA
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
20103010 Biotechnology
Other subject
14 Jan 2022
08:00 CET
INVENTIVA
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
20103010 Biotechnology
Other subject
16 Dec 2021
22:00 CET
INVENTIVA
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
20103010 Biotechnology
Other subject
16 Dec 2021
22:00 CET
INVENTIVA
Inventiva annonce sa participation à la « 40th Annual J.P. Morgan Healthcare Conference »
20103010 Biotechnology
Other subject
06 Dec 2021
22:00 CET
INVENTIVA
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
20103010 Biotechnology
Other subject
06 Dec 2021
22:00 CET
INVENTIVA
Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranor
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva